JP2010512413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512413A5 JP2010512413A5 JP2009541507A JP2009541507A JP2010512413A5 JP 2010512413 A5 JP2010512413 A5 JP 2010512413A5 JP 2009541507 A JP2009541507 A JP 2009541507A JP 2009541507 A JP2009541507 A JP 2009541507A JP 2010512413 A5 JP2010512413 A5 JP 2010512413A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- amphetamine
- disorder
- conjugate
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 25
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 12
- 229940025084 amphetamine Drugs 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 239000007937 lozenge Substances 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 230000003880 negative regulation of appetite Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- -1 troche Substances 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- UDHBXMXHYKXWEF-WCYXVCABSA-N NC(C)CC1=CC=CC=C1.N[C@@H](CCCN)C(=O)O[2H] Chemical group NC(C)CC1=CC=CC=C1.N[C@@H](CCCN)C(=O)O[2H] UDHBXMXHYKXWEF-WCYXVCABSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229940001468 citrate Drugs 0.000 claims 1
- DRLPEFJOKVYESM-JSGCOSHPSA-N lomardexamfetamine Chemical group NC(N)=NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 DRLPEFJOKVYESM-JSGCOSHPSA-N 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 229940042126 oral powder Drugs 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86937506P | 2006-12-11 | 2006-12-11 | |
| PCT/US2007/087028 WO2008073918A1 (en) | 2006-12-11 | 2007-12-10 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010512413A JP2010512413A (ja) | 2010-04-22 |
| JP2010512413A5 true JP2010512413A5 (enExample) | 2010-09-02 |
Family
ID=39512105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009541507A Withdrawn JP2010512413A (ja) | 2006-12-11 | 2007-12-10 | アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7776917B2 (enExample) |
| EP (1) | EP2101571B1 (enExample) |
| JP (1) | JP2010512413A (enExample) |
| CN (1) | CN101594778A (enExample) |
| AT (1) | ATE509622T1 (enExample) |
| AU (1) | AU2007333105A1 (enExample) |
| BR (1) | BRPI0720105A2 (enExample) |
| CA (1) | CA2672138A1 (enExample) |
| ES (1) | ES2364865T3 (enExample) |
| IL (1) | IL198930A0 (enExample) |
| WO (1) | WO2008073918A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| ATE536867T1 (de) | 2006-03-16 | 2011-12-15 | Tris Pharma Inc | Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen |
| US7776917B2 (en) | 2006-12-11 | 2010-08-17 | Mickle Travis C | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
| EP2109465B1 (en) | 2007-02-08 | 2012-04-11 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
| DE102007037478B3 (de) | 2007-08-08 | 2008-04-30 | Leifheit Ag | Wäschetrockenständer |
| US8614346B2 (en) | 2009-06-19 | 2013-12-24 | Cambrex Charles City, Inc. | Methods and compositions for preparation of amphetamine conjugates and salts thereof |
| US20130059914A1 (en) | 2010-04-21 | 2013-03-07 | Signature Therapeutics, Inc. | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof |
| US8779191B2 (en) | 2010-12-20 | 2014-07-15 | Cambrex Charles City, Inc. | Methods and compositions for preparing lisdexamfetamine and salts thereof |
| KR20180069934A (ko) * | 2011-07-28 | 2018-06-25 | 켐팜 인코포레이티드 | 메틸페니데이트 프로드러그, 이의 제조 방법 및 사용 방법 |
| JP2014521641A (ja) * | 2011-07-29 | 2014-08-28 | ケムファーム， インコーポレイテッド | ホモアルギニンプロドラッグおよび／またはアンフェタミンおよび他の興奮剤の抱合体、ならびに同物を作製および使用するためのプロセス |
| US20150182490A1 (en) | 2012-06-26 | 2015-07-02 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| WO2014002039A1 (en) * | 2012-06-27 | 2014-01-03 | Shire Ag | Amphetamine prodrugs |
| EP3530268B1 (en) | 2012-10-09 | 2021-12-15 | Attentive Therapeutics, Inc. | Therapeutic treatment |
| US10314839B2 (en) | 2014-10-20 | 2019-06-11 | Elysium Therapeutics, Inc. | Diversion-resistant opioid formulations |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| WO2017059459A1 (en) | 2015-10-01 | 2017-04-06 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
| US11007144B2 (en) | 2016-11-15 | 2021-05-18 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| DK3551619T3 (da) | 2016-12-11 | 2024-06-10 | Zevra Therapeutics Inc | Sammensætninger, der omfatter methylphenidat-prodrugs, fremgangsmåder til fremstilling og anvendelse heraf |
| WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
| CA3056239C (en) | 2017-03-17 | 2023-09-12 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| JP2020516694A (ja) * | 2017-04-10 | 2020-06-11 | シャイアー ファーマシューティカルズ インコーポレイテッドＳｈｉｒｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | アンフェタミンプロドラッグを使用する治療方法 |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| EP3692042A1 (en) * | 2017-10-06 | 2020-08-12 | Instituto de Medicina Molecular João Lobo Antunes | Treatment of obesity-related conditions |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2019199731A1 (en) * | 2018-04-10 | 2019-10-17 | Shire Pharmaceuticals Inc. | Amphetamine prodrug and crystalline froms thereof |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| WO2020181000A1 (en) * | 2019-03-06 | 2020-09-10 | Ensysce Biosciences, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| JP2023505687A (ja) | 2019-12-11 | 2023-02-10 | インスピルナ，インコーポレーテッド | 癌の処置方法 |
| KR20230174213A (ko) | 2021-03-09 | 2023-12-27 | 엔사이스 바이오사이언시즈 인크. | 나파모스타트의 변형된 방출 조성물 및 그의 사용 방법 |
| CN117715632A (zh) | 2021-03-09 | 2024-03-15 | 恩赛斯生物科学股份有限公司 | 包含酶可裂解的前药和萘莫司他的组合物及其使用方法 |
| EP4392402A4 (en) * | 2021-08-24 | 2025-07-09 | Mind Medicine Inc | SYNTHETIC PATHWAYS TO ACCESS MDMA PRODRUGS USING CONTROLLED AND UNCONTROLLED INTERMEDIATES |
| MX2024003466A (es) | 2021-09-29 | 2024-06-04 | Ensysce Biosciences Inc | Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE539185A (enExample) * | 1954-06-28 | |||
| US2881113A (en) | 1957-01-29 | 1959-04-07 | Ortho Pharma Corp | Therapeutically active compositions containing amphetamines |
| US2892753A (en) * | 1957-02-26 | 1959-06-30 | Boehringer Sohn Ingelheim | Central nervous system stimulant |
| DE1493824A1 (de) | 1964-01-27 | 1969-05-22 | Hoffmann La Roche | Verfahren zur Herstellung von Aminocarbonsaeureamiden |
| TR200001942T2 (tr) | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid agonist/antagonist kombinasyonlar |
| US6503950B1 (en) | 1999-08-23 | 2003-01-07 | David M. Ockert | Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms |
| HK1055078A1 (zh) | 2000-06-09 | 2003-12-24 | The Regents Of The University Of California | 使用纳布啡和鸦片拮抗剂治疗疼痛的方法 |
| US6417184B1 (en) | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| AU2003219863C1 (en) | 2002-02-22 | 2009-03-05 | Shire Llc | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| WO2004091499A2 (en) | 2003-04-09 | 2004-10-28 | Neose Technologies, Inc. | Intracellular formation of peptide conjugates |
| JP4898445B2 (ja) | 2003-05-29 | 2012-03-14 | シャイア エルエルシー | 乱用抵抗性アンフェタミン化合物類 |
| EP1931357A2 (en) | 2005-09-13 | 2008-06-18 | Shire LLC | Prodrugs of phentermine |
| US7776917B2 (en) | 2006-12-11 | 2010-08-17 | Mickle Travis C | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
| EP2109465B1 (en) * | 2007-02-08 | 2012-04-11 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
-
2007
- 2007-12-10 US US11/953,668 patent/US7776917B2/en active Active
- 2007-12-10 WO PCT/US2007/087028 patent/WO2008073918A1/en not_active Ceased
- 2007-12-10 AU AU2007333105A patent/AU2007333105A1/en not_active Abandoned
- 2007-12-10 EP EP07869098A patent/EP2101571B1/en not_active Not-in-force
- 2007-12-10 CN CNA2007800458802A patent/CN101594778A/zh active Pending
- 2007-12-10 AT AT07869098T patent/ATE509622T1/de not_active IP Right Cessation
- 2007-12-10 BR BRPI0720105-2A2A patent/BRPI0720105A2/pt not_active IP Right Cessation
- 2007-12-10 JP JP2009541507A patent/JP2010512413A/ja not_active Withdrawn
- 2007-12-10 CA CA002672138A patent/CA2672138A1/en not_active Abandoned
- 2007-12-10 ES ES07869098T patent/ES2364865T3/es active Active
-
2009
- 2009-05-25 IL IL198930A patent/IL198930A0/en unknown
- 2009-05-28 US US12/473,903 patent/US20090234018A1/en not_active Abandoned
-
2010
- 2010-07-26 US US12/843,169 patent/US8101661B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3007386T3 (en) | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine | |
| JP6530741B2 (ja) | カタプレキシーの治療 | |
| ES2364865T3 (es) | Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos. | |
| JP6479670B2 (ja) | ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法 | |
| JP2009525343A5 (enExample) | ||
| JP2010047578A5 (enExample) | ||
| JP2023519965A5 (enExample) | ||
| ES2654615T3 (es) | Compuestos de carbamato para el tratamiento del trastorno bipolar | |
| JP2005537268A5 (enExample) | ||
| ES2968840T3 (es) | Compuestos de aminocarbonilcarbamato y su uso en el tratamiento de trastornos hipercinéticos tales como el TDAH | |
| CN111201014A (zh) | 治疗过度嗜睡的方法和组合物 | |
| JP2010518122A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2016106150A5 (enExample) | ||
| JP2019503365A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2012521435A5 (enExample) | ||
| JP2002532392A5 (enExample) | ||
| JP2016185995A5 (enExample) | ||
| JP2013528600A5 (enExample) | ||
| PT2701693T (pt) | Tapentadol para prevenção e tratamento de depressão e ansiedade | |
| WO2017208031A1 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| JP2013516488A (ja) | 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療 | |
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| CN101955440B (zh) | 一种阿戈美拉汀新晶型及其制备方法 |